A Phase 2 interventional study of CS0159 (Linafexor) in Nonalcoholic Steatohepatitis (NASH), sponsored by Cascade Pharmaceuticals, Inc. Completed at 17 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Cascade Pharmaceuticals, Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 166th largest by enrollment of the 460 interventional ones that give a count, is one of 37 that started in 2023, is one of 192 in phase 2, and was the 461st registered.
1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
Regeneron Pharmaceuticals · Sites in United States, Puerto Rico, United Kingdom
Ages 18–75
Columbia University · Sites in United States
Ages 18–65
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
GlaxoSmithKline · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
547 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 93 · Phase 2 213 · Phase 3 36 · Phase 4 13
First in 2000; this study’s year is marked. 37 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 99 is above the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 56 across the 460 interventional studies, 90 across the 85 observational. Of the 420 that completed or were terminated, 216 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
246 of 547 have an industry lead sponsor. The 10 most frequent:
Cascade Pharmaceuticals, Inc is the lead sponsor of 14 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Cascade Pharmaceuticals, Inc has 1 study filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
22 of the studies in Non-alcoholic Fatty Liver Disease with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04951219Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | 2027-03 |
| NCT04833140Phase 3Massachusetts General HospitalEstrogen Administration for the Treatment of NASH in Postmenopausal Women | 2027-07-09 |
| NCT00983463Vanderbilt UniversityAbundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD) | 2026-11 |
| NCT05165706Stanford UniversityLongitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance | 2026-11-30 |
| NCT05067621Yale UniversitySemaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A randomized, double-blind study to assess the safety, tolerability, PK and efficacy of CS0159 in subjects with Non-Alcoholic Steatohepatitis (NASH)
This will be a multicenter, double-blind, randomized, placebo-controlled, dose-ranging study to evaluate the safety, tolerability, PKs, and efficacy of CS0159 in the treatment of patients with NASH over 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Total > (ULN; except for patients with Gilbert's syndrome with a normal direct bilirubin value and normal reticulocyte count).
count \<140 000/mm³, \<1500 cells/mm3, or total
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One tablet daily for 12 weeks
Drug: CS0159 (Linafexor)
One tablet daily for 12 weeks
Drug: CS0159 (Linafexor)
One tablet daily for 12 weeks
Drug: CS0159 (Linafexor)
Oral QD
Also known as: placebo
MRI-PDFF
To assess the percentage changes in liver steatosis through magnetic resonance imaging (MRI) proton density fat fraction (PDFF) from baseline to Week 12
Time frame: Week 12
Adverse Events
To evaluate the safety and tolerability of CS0159 in patients with NASH treated over 12 weeks
Time frame: Week 12
Cmax
maximum concentration (Cmax)
Time frame: Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.
Tmax
time to maximum plasma concentration (tmax)
Time frame: Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.
t1/2
half-life (t1/2)
Time frame: Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.
AR(AUC)
accumulation ratio of area under the concentration-time curve (AUC) in plasma from baseline to day42
Time frame: Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.
Pharmacodynamics (PD)-Fibroblast Growth Factor 19
Plasma concentrations and PD parameters of the biomarkers of FXR target engagement fibroblast growth factor 19 from baseline to day42
Time frame: Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.
Pharmacodynamics (PD)-C4
Plasma concentrations and PD parameters of the biomarkers of FXR target engagement 7-alpha-Hydroxy-4-cholesten-3-one(C4) from baseline to day42
Time frame: Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.
This multicenter study was conducted at 17 sites in the United States of America between 10 February 2023 and 04 May 2023
| Milestone | 1.4mg CS0159 | 2mg CS0159 | PLACEBO |
|---|---|---|---|
| Started | 39 | 40 | 20 |
| Completed | 34 | 37 | 19 |
| Not completed | 5 | 3 | 1 |
To assess the percentage changes in liver steatosis through magnetic resonance imaging (MRI) proton density fat fraction (PDFF) from baseline to Week 12
| percentage change | 1.4mg CS0159 | 2mg CS0159 | PLACEBO |
|---|---|---|---|
| MRI-PDFF | -4.08 ± 47.042 | -14.10 ± 27.227 | -4.34 ± 24.563 |
To evaluate the safety and tolerability of CS0159 in patients with NASH treated over 12 weeks
| Participants | 1.4mg CS0159 | 2mg CS0159 | PLACEBO |
|---|---|---|---|
| Adverse Events | 22 | 22 | 11 |
maximum concentration (Cmax)
| ng/mL | 1.4mg CS0159(day1) | 2mg CS0159(day1) | 1.4mg CS0159(day42) | 2mg CS0159(day42) |
|---|---|---|---|---|
| Cmax | 10.3 ± 95.7 | 15.6 ± 56.3 | 10.1 ± 60.6 | 16.4 ± 45.9 |
time to maximum plasma concentration (tmax)
| h | 1.4mg CS0159(day1) | 2mg CS0159(day1) | 1.4mg CS0159(day42) | 2mg CS0159(day42) |
|---|---|---|---|---|
| Tmax | 0.550 (0.467 to 3.00) | 0.950 (0.500 to 1.33) | 0.550 (0.483 to 1.02) | 0.550 (0.500 to 1.02) |
half-life (t1/2)
| h | 1.4mg CS0159(day1) | 2mg CS0159(day1) | 1.4mg CS0159(day42) | 2mg CS0159(day42) |
|---|---|---|---|---|
| t1/2 | 1.17 ± 37.5 | 1.15 ± 24.9 | 1.36 ± 27.8 | 1.17 ± 27.7 |
accumulation ratio of area under the concentration-time curve (AUC) in plasma from baseline to day42
| Unitless | 1.4mg CS0159 | 2mg CS0159 |
|---|---|---|
| AR(AUC) | 1.02 ± 29.2 | 0.944 ± 24.4 |
Plasma concentrations and PD parameters of the biomarkers of FXR target engagement fibroblast growth factor 19 from baseline to day42
| pg/mL | 1.4mg CS0159(day1) | 2mg CS0159(day1) | Placebo(day1) | 1.4mg CS0159(day42) | 2mg CS0159(day42) | Placebo(day42) |
|---|---|---|---|---|---|---|
| predose | 138.38 ± 121.702 | 128.09 ± 148.453 | 140.59 ± 102.064 | 113.07 ± 130.626 | 134.27 ± 154.692 | 139.38 ± 93.679 |
| 0.5h | 92.79 ± 89.338 | 110.25 ± 144.398 | 164.64 ± 144.567 | 77.26 ± 56.454 | 85.91 ± 89.842 | 110.21 ± 88.913 |
| 1h | 118.56 ± 86.303 | 107.55 ± 103.224 | 151.99 ± 99.154 | 130.84 ± 156.455 | 313.98 ± 1067.777 | 126.65 ± 85.892 |
| 1.5h | 111.35 ± 92.887 | 177.04 ± 141.541 | 155.91 ± 113.146 | 106.49 ± 119.510 | 136.41 ± 103.774 | 117.81 ± 86.580 |
| 2h | 302.80 ± 310.163 | 383.05 ± 274.093 | 150.88 ± 105.402 | 279.22 ± 250.961 | 503.97 ± 412.934 | 134.60 ± 107.081 |
| 3h | 857.76 ± 604.031 | 874.42 ± 412.733 | 148.72 ± 100.988 | 760.87 ± 439.389 | 1093.75 ± 571.917 | 206.28 ± 141.046 |
| 5h | 899.63 ± 497.648 | 1198.97 ± 490.641 | 196.83 ± 141.328 | 1038.65 ± 775.037 | 1092.79 ± 546.569 | 261.29 ± 145.023 |
Plasma concentrations and PD parameters of the biomarkers of FXR target engagement 7-alpha-Hydroxy-4-cholesten-3-one(C4) from baseline to day42
| ng/mL | 1.4mg CS0159(day1) | 2mg CS0159(day1) | 1.4mg CS0159(day42) | 2mg CS0159(day42) | Placebo(day1) | Placebo(day42) |
|---|---|---|---|---|---|---|
| predose | 43.594 ± 51.4909 | 42.536 ± 41.4767 | 34.863 ± 33.5972 | 34.703 ± 27.7719 | 30.506 ± 22.3276 | 48.996 ± 48.8304 |
| 0.5 h | 57.836 ± 68.0985 | 32.835 ± 23.2534 | 37.306 ± 41.1756 | 30.279 ± 16.6718 | 27.614 ± 20.7212 | 44.609 ± 41.4394 |
| 1h | 51.170 ± 63.2339 | 38.959 ± 37.4650 | 43.553 ± 48.7988 | 35.549 ± 27.2340 | 30.622 ± 21.3313 | 44.692 ± 40.7742 |
| 1.5h | 69.451 ± 84.9413 | 31.223 ± 20.4114 | 39.218 ± 45.4658 | 33.472 ± 19.9611 | 26.792 ± 17.0100 | 45.776 ± 40.0685 |
| 2h | 66.830 ± 82.2063 | 27.834 ± 17.9538 | 39.639 ± 44.8513 | 31.833 ± 18.9725 | 23.023 ± 12.6272 | 51.759 ± 45.0546 |
| 3h | 54.829 ± 61.2353 | 22.233 ± 13.8929 | 46.215 ± 51.5511 | 25.724 ± 14.1861 | 16.446 ± 8.9966 | 55.370 ± 42.5373 |
| 5h | 25.147 ± 29.2499 | 13.454 ± 8.2293 | 45.214 ± 48.8811 | 14.445 ± 8.5253 | 8.548 ± 5.6910 | 47.482 ± 33.3965 |
Collected over from enrollment until end of follow-up, up to 16 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1.4mg CS0159 | 0/39 (0%) | 0/39 (0%) | 22/39 (56.4%) |
| 2mg CS0159 | 0/40 (0%) | 2/40 (5%) | 20/40 (50%) |
| PLACEBO | 0/20 (0%) | 1/20 (5%) | 10/20 (50%) |
| Event | 1.4mg CS0159 | 2mg CS0159 | PLACEBO |
|---|---|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/39 | 0/40 | 1/20 |
| Femur fractureInjury, poisoning and procedural complications | 0/39 | 1/40 | 0/20 |
| AppendicitisInfections and infestations | 0/39 | 1/40 | 0/20 |
| Event | 1.4mg CS0159 | 2mg CS0159 | PLACEBO |
|---|---|---|---|
| PruritusSkin and subcutaneous tissue disorders | 7/39 | 9/40 | 5/20 |
| HyperglycaemiaMetabolism and nutrition disorders | 3/39 | 5/40 | 0/20 |
| Abdominal pain upperGastrointestinal disorders | 4/39 | 0/40 | 0/20 |
| ContusionInjury, poisoning and procedural complications | 4/39 | 1/40 | 2/20 |
| Skin lacerationInjury, poisoning and procedural complications | 0/39 | 0/40 | 2/20 |
| Upper respiratory tract infectionInfections and infestations | 0/39 | 3/40 | 0/20 |
| FlatulenceGastrointestinal disorders | 2/39 | 2/40 | 0/20 |
| ConstipationGastrointestinal disorders | 2/39 | 0/40 | 1/20 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 2/39 | 2/40 | 0/20 |
| HeadacheNervous system disorders | 2/39 | 1/40 | 0/20 |
| Age, Continuous(years) | 1.4mg CS0159 | 2mg CS0159 | PLACEBO | Total |
|---|---|---|---|---|
| Mean | 55.7 ± 9.68 | 53.7 ± 11.96 | 57.7 ± 9.18 | 55.3 ± 10.58 |
| Sex: Female, Male(Participants) | 1.4mg CS0159 | 2mg CS0159 | PLACEBO | Total |
|---|---|---|---|---|
| Female | 17 | 20 | 8 | 45 |
| Male | 22 | 20 | 12 | 54 |
| Race (NIH/OMB)(Participants) | 1.4mg CS0159 | 2mg CS0159 | PLACEBO | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 1 |
| Asian | 0 | 2 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 6 | 1 | 8 |
| White | 37 | 31 | 17 | 85 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 0 | 2 |
| Ethnicity (NIH/OMB)(Participants) | 1.4mg CS0159 | 2mg CS0159 | PLACEBO | Total |
|---|---|---|---|---|
| Hispanic or Latino | 23 | 23 | 12 | 58 |
| Not Hispanic or Latino | 15 | 17 | 8 | 40 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| MRI-PDFF(percentage of liver fat content) | 1.4mg CS0159 | 2mg CS0159 | PLACEBO | Total |
|---|---|---|---|---|
| Mean | 17.70 ± 6.121 | 15.71 ± 6.944 | 15.95 ± 5.833 | 16.54 ± 6.419 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2023 to primary completion in Nov 2023, 8 months.
Results were first posted in Nov 2026, 3 years after primary completion.
Of 53 non-industry phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 56. This study's 8 months is below that.
Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Linafexor
Non-alcoholic Fatty Liver Disease →
Cascade Pharmaceuticals, Inc